MediaPress Releases Archives Media Inquiries In the News Press Releases FEATURED PRESS RELEASE June 12, 2024Cranbury Pharmaceuticals Receives U.S. FDA Approval for First Generic Version of Emflaza® Oral Suspension (deflazacort) for Duchenne Muscular Dystrophy May 29, 2024Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication April 16, 2024Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD February 7, 2024Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance January 22, 2024Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer and Vice President, General Counsel